1. Catalog
  2. Innovations in the Surgical Treatment of BPH Webca ...
Innovations in the Surgical Treatment of BPH Webcast & Podcast (2026)
Availability
On-Demand
2 Courses
Cost
$0.00
Credit Offered
2 AMA PRA Category 1 Credit Credits
2 Participation Credits


As a direct result of the evolving technologies and procedures related to the surgical management of BPH, urologists must continue increasing their knowledge and skills of the various treatment options available.

Designed for urologists and other healthcare professionals involved in the treatment of BPH, this 2-hour, interactive discussion-based course, will provide a practical application on how the newly released Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Clinical Guideline (2026) applies in day-to day practice with a patient centered focus.

Led by renowned experts in the field, the course will also discuss the evidence base for several surgical techniques including temporary implantable nitinol devices, bipolar enucleation, and intraprostatic drug coated balloon techniques.

Presented in English with simultaneous translations in over fifty languages using Wordly, this activity is of value to the global urologic community.

ACKNOWLEDGEMENTS:

Support provided by  independent educational grants from:
  • Olympus Corporation of the Americas
  • Telefelx Interventional Urology
  • Urologists
  • Residents
  • Advanced Practice Providers

After participating in this educational series, participants will be able to:

  1. Utilize the newly released AUA Guidelines Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice.
  2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.
  3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.
  4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.

FACULTY DISCLOSURES

Name Company Name Relationship Type End Date
Anderson, Paul David ProVerum Scientific Study or Trial Current
Merck Sharp & Dohme LLC Scientific Study or Trial Current
Boston Scientific Scientific Study or Trial Current
Contraline Scientific Study or Trial Current
Zenflow Scientific Study or Trial Current
Miller, Nicole Lara Ambu Consultant or Advisor Current
Boston Scientific Scientific Study or Trial Current
Lumibird Consultant or Advisor Current
Ventaris Surgical Consultant or Advisor Current
Novo Nordisk Consultant or Advisor Current
Akeeko Medical Consultant or Advisor Current
Sandhu, Jaspreet Singh No relevant financial relationships to disclose
Warner, Jonathan N. Olympus Consultant or Advisor Current
Welliver, Charles No relevant financial relationships to disclose

EDUCATION COUNCIL DISCLOSURE

Education Council DTL 2025.pdf

COI REVIEW WORK GROUP DISCLOSURES

COI Review Workgroup DTL 2025.pdf

AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.